Abstract:

Cervical cancer, ovarian cancer and endometrial cancer are common gynecological malignancies with increasing incidence and younger age groups, which seriously threatens women′s health. Although the conditions of some patients can be improved after standardized treatment, a large proportion of patients still have deteriorating conditions and poor prognosis, and there is an urgent need to find new targets for precise treatment and improved prognosis. Trophoblast cell surface antigen 2 (Trop-2) is a transmembrane glycoprotein that is highly expressed in various tumor tissues, and plays an important role in the proliferation, invasion and metastasis of cervical, endometrial and ovarian cancers through cell surface receptor signaling, making it an important potential marker for early diagnosis, and can be used to access tumor progression and patient prognosis. In the therapeutic aspect, targeted therapeutic strategies such as antibody-drug conjugate (ADC) against Trop-2 have shown promising applications. For example, sacituzumab govitecan (SG), as an ADC targeting Trop-2, has achieved remarkable efficacy in the treatment of gynecological malignancies and has been incorporated into relevant clinical application guidelines. At present, a number of clinical trials of ADC drugs targeting Trop-2 are actively underway, and Trop-2 is expected to play an increasingly important role in the early detection and treatment of gynecological malignant tumors, and bring patients greater hope for survival.

Key words: Trophoblast cell surface antigen 2, Antibody-drug conjugate, Uterine cervical neoplasms, Ovarian neoplasms, Endometrial neoplasms, Therapy, Prognosis